¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen excess zone"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • antigen, labelled
    Ç¥ÁöÇ׿ø
  • antigen, leukocyte
    ¹éÇ÷±¸Ç׿ø
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • antigen, major histocompatibility
    ÁÖÁ¶Á÷ÀûÇÕÇ׿ø, MHCÇ׿ø
  • antigen, particulate
    ÀÔÀÚÇ׿ø
  • antigen, polymerized
    ÁßÇÕüÇ׿ø
  • antigen, private
    °³ÀÎÇ׿ø, °³º°Ç׿ø
  • antigen, protective
    ¹æ¾îÇ׿ø
  • antigen, public
    ÀϹÝÇ׿ø, °øÅëÇ׿øcf.private antigen
  • antigen, self
    ÀÚ°¡Ç׿ø, ÀÚ±âÇ׿ø
  • antigen, sequestered
    °Ý¸®Ç׿ø
  • antigen, serologically defined
    Ç÷ûÇÐÀû ±ÔÁ¤Ç׿ø, SDÇ׿ø
  • antigen, soluble
    ¼ö¿ë¼ºÇ׿ø
  • antigen, somatic
    ü¼¼Æ÷Ç׿ø
  • antigen, species-specific
    Á¾Æ¯ÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • antigen presentation
    Ç׿øÁ¦°ø, Ç׿øÀü´Þ, Ç׿øÁ¦½Ã
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen presenting cells
    Ç׿ø Àü´Þ ¼¼Æ÷
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • antigen recognition
    Ç׿øÀÎÁö
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • antigen recognizing cell
    Ç׿ø½Äº°¼¼Æ÷.
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • antigen unit
    Ç׿ø´ÜÀ§.
  • antigen variation
    Ç׿øº¯ÀÌ.
  • antigen, Australia
    ¿À½ºÆ®·¹Àϸ®¾ÆÇ׿ø, BÇü °£¿°¹ÙÀÌ·¯½º
  • antigen, Boivins
    º¸À̺óÇ׿ø
  • antigen, D-related
    D-°ü·ÃÇ׿ø
  • antigen, Forssmans
    Æ÷½º¸¸Ç׿ø
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
LUZ left upper zone
MTL mantle zone lymphoma
MZ mantle zone; meziocillin; monozygotic
NTZ normal transformation zone
NZ normal zone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
anti HBc Antibody to hepatitis B core antigen
anti-HBe Antibody to hepatitis B e antigen
anti HBs Antibody to hepatitis B surface antigen
Ag Antigen
a Antigen
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
heterophile antigen An antigen or antigenic determinant which is found in different tissues in more than one species.
(05 Mar 2000)
Xg antigen xg blood group
histocompatibility antigen <immunology> A set of plasmalemmal glycoproteins on the surface of all nucleated cells that are crucial for T-cell recognition of antigens. Particularly the HLA system in humans and the H2 system in mice. They are the major antigens responsible for tissue recognition. For this reason, they are of prime importance in determining compatible organ donors for a specific transplantation procedure. Each person has unique HLA antigens. Some HLA antigens have been identified to be correlated with the presence of certain autoimmune diseases. One of these is the HLA-B27 site. Approximately 85% of patients with ankylosing spondylitis and Reiter's syndrome will have the HLA-B27 antigen present on the leukocytes.
There are two classes of histocompatibility antigens:
1. Class I, histocompatibility antigens composed of two glycosylated subunits, a heavy chain of 44 kD and beta2 microglobulin (12 kD). The heavy chain may be coded by K, D or L genes of mouse H2 and A, B or C genes of human HLA complex. Class I antigens are important in T-cell killing and are recognised in conjunction with the foreign cell surface antigens MHC restriction).
2. Class II antigens, heterodimeric histocompatibility antigens composed of alpha (32 kD) and beta (28 kD) chains. Found mostly on B lymphocytes, macrophages and accessory cells. The response of T helper cells requires that the foreign antigen is presented in conjunction with the appropriate Class II antigens. (Murine H2 Ia antigens and human HLA DR antigens are Class II).
(14 Oct 1997)
HLA-a1 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. Individuals bearing this allele are more susceptible to hodgkin's disease. HLA-a1 is in linkage disequilibrium with HLA-b8 and HLA-dr3.
(12 Dec 1998)
HLA-a2 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The HLA-a2 antigen is associated with recognition of the influenza a virus.
(12 Dec 1998)
HLA-a3 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the a locus on chromosome 6. The allele occurs with increased frequency in individuals with idiopathic haemochromatosis. HLA-a3 is in linkage disequilibrium with HLA-b7 and HLA-dr2.
(12 Dec 1998)
HLA-b27 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is strongly associated with acute anterior uveitis, ankylosing spondylitis, and reiter's disease.
Increased frequency of antigen in: ankylosing spondylitis (90%), Reiter syndrome (90%), enteropathic arthritis (75%), psoriatic arthritis (60%) normal frequency: white: 8%, black: 4%
(12 Dec 1998)
HLA-b35 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is weakly associated with a number of diseases.
(12 Dec 1998)
HLA-b7 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. There is a weak association between the presence of the HLA-b7 antigen and the diseases of narcolepsy and idiopathic haemochromatosis. HLA-b7 is in linkage disequilibrium with HLA-a3 and HLA-dr2.
(12 Dec 1998)
HLA-b8 antigen <immunology> Human histocompatibility (HLA) surface antigen encoded by the b locus on chromosome 6. It is in linkage disequilibrium with HLA-a1 and HLA-dr3. This explains the fact that though HLA-b8 was originally associated with several diseases, including coeliac disease, dermatitis herpetiformis, and myasthenia gravis, their association with HLA-dr3 is now considered more significant.
(12 Dec 1998)
HLA-dr1 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells.
(12 Dec 1998)
HLA-dr2 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-a3 and HLA-b7 and is strongly associated with goodpasture syndrome, multiple sclerosis, and narcolepsy.
(12 Dec 1998)
HLA-dr3 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is in linkage disequilibrium with HLA-a1 and HLA-b8. The HLA-dr3 antigen is strongly associated with coeliac disease, grave's disease, dermatitis herpetiformis, early-age onset myasthenia gravis, systemic lupus erythematosus, juvenile diabetes, and opportunistic infections in aids.
(12 Dec 1998)
HLA-dr4 antigen <immunology> Human immune-response, d-related antigen encoded by the d locus on chromosome 6 and found on lymphoid cells. It is strongly associated with rheumatoid arthritis and juvenile diabetes.
(12 Dec 1998)
HLA-dr5 antigen <immunology> Human immune-response, d-related antigen encoded by the d-locus on chromosome 6 and found on lymphoid cells. It is associated with kaposi sarcoma in aids and juvenile rheumatoid arthritis.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á